
Please try another search
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing TLX250-CDx, a positron emission tomography (PET) diagnostic imaging agent for the characterization of renal masses as clear cell renal cell carcinoma; TLX101-CDx, a PET diagnostic agent to image cancerous lesions in the brain; and TLX66-CDx, a cluster of differentiation 66 imaging agent for osteomyelitis (bone infection). It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Name | Age | Since | Title |
---|---|---|---|
Chaitanya R. Divgi | - | - | Member of the Scientific Advisory Board |
Jason Lewis | - | - | Member of the Scientific Advisory Board |
Frederik L. Giesel | - | 2020 | Member of Scientific Advisory Board |
Samuel Samnick | - | - | Member of the Scientific Advisory Board |
Klaus Kopka | - | - | Member of the Scientific Advisory Board |
Richard Zimmermann | - | 2017 | Member of Scientific Advisory Board |
Richard P. Baum | - | - | Member of the Scientific Advisory Board |
Rodney W. Hicks | - | - | Member of the Scientific Advisory Board |
Jean-François Chatal | - | - | Member of the Scientific Advisory Board |
Jann Elizabeth Skinner | 67 | 2018 | Independent Non-Executive Director |
Neil H. Bander | - | - | Member of the Scientific Advisory Board |
Christian P. Behrenbruch | 49 | 2017 | Co-Founder, MD, Group CEO & Executive Director |
Marie McDonald | - | 2025 | Independent Non-Executive Director |
Stefano Fanti | - | 2019 | Scientific Advisor |
Tiffany P. Olson | 66 | 2022 | Independent Chairman of the Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review